

IDS - 04/10/2006

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10506729
	Filing Date		2004-09-03
	First Named Inventor	Andrew Stocker	
	Art Unit	1626	
	Examiner Name	BARKER, MICHAEL P	
	Attorney Docket Number	100664-1P US	

U.S. PATENTS							Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Patent citation information please click the Add button.							Add	
U.S. PATENT APPLICATION PUBLICATIONS							Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear		
MB	1	20040266768		2004-12-30	Schoenafinger et al.			
MB	2	20040142938		2004-07-22	Sher et al.			
MB	3	20040220229		2004-11-04	Bussolotti et al.			
If you wish to add additional U.S. Published Application citation information please click the Add button.							Add	
FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
MB	1	2004113345	WO	A1	2004-12-29	Japan Tobacco Inc.		<input checked="" type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10506729
Filing Date	2004-09-03
First Named Inventor	Andrew Stocker
Art Unit	1626
Examiner Name	BARKER, MICHAEL P
Attorney Docket Number	100664-1P US

MB	2	03/045920	WO	A1	2003-06-05	Merck & Co., Inc.		<input type="checkbox"/>
	3	03/072570	WO	A1	2003-09-04	Pfizer Products Inc.		<input type="checkbox"/>
	4	1 340 500	EP	A1	2003-09-03	Pfizer Products Inc.		<input type="checkbox"/>
	5	2004/041780	WO	A2	2004-05-21	Pfizer Products Inc.		<input type="checkbox"/>
	6	2004/092158	WO	A1	2004-10-28	Pfizer Products Inc.		<input type="checkbox"/>
	7	1 338 594	EP	A1	2003-08-27	Shionogi & Co., Ltd.		<input type="checkbox"/>
	8	03/091213	WO	A1	2003-11-06	Yamanouchi Pharmaceutical Co., Ltd.		<input checked="" type="checkbox"/>
	9	2004196702	JP	A	2004-07-15	Yamanouchi Pharmaceutical Co., Ltd.		<input checked="" type="checkbox"/>
	10	2005/013981	WO	A1	2005-02-17	AstraZeneca AB		<input type="checkbox"/>
	11	2005/013975	WO	A1	2005-02-17	AstraZeneca AB		<input type="checkbox"/>
MB	12	2005/020986	WO	A1	2005-03-10	AstraZeneca AB		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10506729
Filing Date		2004-09-03
First Named Inventor	Andrew Stocker	
Art Unit	1626	
Examiner Name	BARKER, MICHAEL P	
Attorney Docket Number	100664-1P US	

MB	13	2005/020985	WO	A1	2005-03-10	AstraZeneca AB		<input type="checkbox"/>
	14	2005/019172	WO	A1	2005-03-03	AstraZeneca AB		<input type="checkbox"/>
	15	2005/018637	WO	A1	2005-03-03	AstraZeneca AB		<input type="checkbox"/>
	16	2005/020987	WO	A1	2005-03-10	AstraZeneca AB		<input type="checkbox"/>
	17	2004/104001	WO	A2	2004-12-02	OSI Pharmaceuticals Inc		<input type="checkbox"/>
	18	01/32622	WO	A1	2001-05-10	AstraZeneca AB		<input type="checkbox"/>
	19	02/20530	WO	A1	2002-03-14	AstraZeneca AB		<input type="checkbox"/>
	20	03/074484	WO	A1	2003-09-12	AstraZeneca AB		<input type="checkbox"/>
	21	03/074485	WO	A2	2003-09-12	AstraZeneca AB		<input type="checkbox"/>
	22	03/074532	WO	A1	2003-09-12	AstraZeneca AB		<input type="checkbox"/>
MB	23	03/074531	WO	A1	2003-09-12	AstraZeneca AB		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10506729
Filing Date		2004-09-03
First Named Inventor	Andrew Stocker	
Art Unit	1626	
Examiner Name	BARKER, MICHAEL P	
Attorney Docket Number	100664-1P US	

MB	24	03/074513	WO	A2	2003-09-12	AstraZeneca AB		<input type="checkbox"/>
MB	25	2004/031193	WO	A1	2004-04-15	AstraZeneca AB		<input type="checkbox"/>
MB	26	2004/031194	WO	A1	2004-04-15	AstraZeneca AB		<input type="checkbox"/>
MB	27	2001247565	JP	A	2001-09-11	Pfizer Prod Inc		<input checked="" type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

Add

NON-PATENT LITERATURE DOCUMENTS

Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
MB	1	Font, M. et al. "Indoles and pyridazino[4,5-b]indoles as nonnucleoside analog inhibitors of HIV-1 reverse transcriptase", European Journal Med Chem (1995), 30(12), 963-71	<input type="checkbox"/>
MB	2	Lin, T. et al. "Effects of Protein Binding and Experimental Disease States on Brain Uptake of Benzodiazepines in Rats", J Pharmacology & Eptl Therapeutics (1990), 253(1), 45-50	<input type="checkbox"/>
MB	3	Varnavas, A. et al. "Quinolone Derivatives: Synthesis and Binding Evaluation on Cholecystokinin Receptors", Farmaco (1996), 51(5), 341-350	<input type="checkbox"/>
MB	4	Parsons, W H. et al. "Cholecystokinin Antagonists. Synthesis and Biological Evaluation of 3-Substitued Benzolactams", J Med Chem (1989), 32(8), 1681-5	<input type="checkbox"/>
MB	5	Vertigan, H. et al. "Impact of cell glycogen content on modulation of hepatocyte glucose metabolism by pharmacological agents", EASD Munich 2004	<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10506729
	Filing Date		2004-09-03
	First Named Inventor	Andrew Stocker	
	Art Unit	1626	
	Examiner Name	BARKER, MICHAEL P	
	Attorney Docket Number	100664-1P US	

MB	6	Bartlett, J. et al. "In Vitro and In Vivo Profile of Gpi688, a Novel, Potent Inhibitor of Glycogen Phosphorylase", ADA San Diego 2005	<input type="checkbox"/>
MB	7	Green, A R. et al. "The Glycogenic Action of Protein Targeting to Glycogen in Hepatocytes Involves Multiple Mechanisms Including Phosphorylase Inactivation and Glycogen Synthase Translocation", J Biol Chem, 279(45), 46474-46482, 2004	<input type="checkbox"/>
MB	8	Roberts, P A. et al. " The temporal relationship between glycogen phosphorylase and activation of the pyruvate dehydrogenase complex during adrenaline infusion in resting canine skeletal muscle", J Physiology-London 545(1), 297-304, 2002	<input type="checkbox"/>
MB	9	Simpson, I. et al. "Novel Orally Active Amino-indan Inhibitors of Glycogen Phosphorylase", Cambridge Med Chem Conference, Sept 2005. Poster EOM	<input type="checkbox"/>
MB	10	Crochet, R.A., et al., J. Het. Chem., "Synthesis of Substituted Thieno[2,3-b] pyrroles," Vol. 11, 143-150 (April 1974).	<input type="checkbox"/>
MB	11	Teague, J., "Mobilisation of Tissue Glycogen Following Inhibition of Glycogen Phosphorylase in fa/fa Rat," Diabetes, 52, Supp. 2, A365, 1521-P (2003).	<input type="checkbox"/>
MB	12	Vertigan, H., "Impact of cell glycogen content on modulation of hepatocyte glucose metabolism by pharmacological agents," Diabetologia, 47, Supp.1, 589, A214. (2004),	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Michael Barker/	Date Considered	08/24/2006
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10506729
	Filing Date		2004-09-03
	First Named Inventor	Andrew Stocker	
	Art Unit	1626	
	Examiner Name	BARKER, MICHAEL P	
	Attorney Docket Number	100664-1P US	

MB	1	OIKONOMAKOS, N.G., et al., Allosteric inhibition of glycogen phosphorylase alpha by the potential antidiabetic drug 3-isopropyl 4-(2-chlorophenyl)-1,4-dihydro-1-ethyl-2-methyl-pyridine-3,5,6-tricarboxylate, Protein Science, 1999, 1930-1945, 8, Cambridge University Press, USA.	<input type="checkbox"/>
If you wish to add additional non-patent literature document citation information please click the Add button <input type="button" value="Add"/>			
EXAMINER SIGNATURE			
Examiner Signature	/Michael Barker/		Date Considered 08/24/2006
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			
<small> ¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached. </small>			